8,154 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Bought by Altiora Financial Group LLC

Altiora Financial Group LLC bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD) in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 8,154 shares of the biopharmaceutical company’s stock, valued at approximately $684,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Avior Wealth Management LLC raised its stake in shares of Gilead Sciences by 1.2% during the 3rd quarter. Avior Wealth Management LLC now owns 9,422 shares of the biopharmaceutical company’s stock valued at $782,000 after buying an additional 108 shares during the last quarter. Concord Asset Management LLC VA raised its stake in shares of Gilead Sciences by 3.8% during the 3rd quarter. Concord Asset Management LLC VA now owns 3,056 shares of the biopharmaceutical company’s stock valued at $256,000 after buying an additional 111 shares during the last quarter. TFB Advisors LLC raised its stake in shares of Gilead Sciences by 1.2% during the 3rd quarter. TFB Advisors LLC now owns 9,397 shares of the biopharmaceutical company’s stock valued at $788,000 after buying an additional 116 shares during the last quarter. Sumitomo Life Insurance Co. raised its stake in shares of Gilead Sciences by 0.7% during the 3rd quarter. Sumitomo Life Insurance Co. now owns 17,822 shares of the biopharmaceutical company’s stock valued at $1,494,000 after buying an additional 117 shares during the last quarter. Finally, FDx Advisors Inc. raised its stake in shares of Gilead Sciences by 2.2% during the 3rd quarter. FDx Advisors Inc. now owns 5,365 shares of the biopharmaceutical company’s stock valued at $450,000 after buying an additional 117 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analyst Ratings Changes

GILD has been the subject of a number of recent research reports. Sanford C. Bernstein initiated coverage on Gilead Sciences in a research note on Thursday, October 17th. They set an “outperform” rating and a $105.00 price objective for the company. Leerink Partners upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating and raised their target price for the company from $74.00 to $96.00 in a research report on Monday, October 21st. Wells Fargo & Company raised their target price on Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Wolfe Research assumed coverage on Gilead Sciences in a research report on Friday, November 15th. They set an “outperform” rating and a $110.00 target price on the stock. Finally, Truist Financial raised their target price on Gilead Sciences from $83.00 to $97.00 and gave the company a “hold” rating in a research report on Friday, November 8th. Twelve research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and four have given a strong buy rating to the stock. Based on data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $95.41.

Gilead Sciences Trading Up 1.4 %

Shares of Gilead Sciences stock opened at $89.84 on Friday. The stock has a market cap of $111.96 billion, a P/E ratio of 998.22, a P/E/G ratio of 2.72 and a beta of 0.17. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The stock’s 50 day simple moving average is $87.28 and its 200-day simple moving average is $76.61. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $98.90.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating the consensus estimate of $1.58 by $0.44. The firm had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The business’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.29 EPS. Analysts predict that Gilead Sciences, Inc. will post 4.38 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 30th. Stockholders of record on Friday, December 13th will be given a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 3.43%. The ex-dividend date of this dividend is Friday, December 13th. Gilead Sciences’s payout ratio is presently 3,422.22%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 25,590 shares of the business’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total value of $2,341,485.00. Following the sale, the insider now owns 99,599 shares of the company’s stock, valued at $9,113,308.50. The trade was a 20.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Johanna Mercier sold 29,357 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the sale, the insider now directly owns 78,127 shares in the company, valued at approximately $6,545,480.06. The trade was a 27.31 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 56,947 shares of company stock valued at $4,968,674 over the last quarter. 0.16% of the stock is owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.